SCHEMBL27052004

SCHEMBL27052004

CC(C)c1c(Cl)cc2nc(N)sc2c1C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.46
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
SCN4A P35499 1/20 0.42
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MAPT P10636 1/20 0.35
HTT P42858 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
LMNA P02545 2/20 0.32
GLP1R P43220 2/20 0.32
AXL P30530 1/20 0.32
GFER P55789 1/20 0.32
GAA P10253 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
PDE10A Q9Y233 1/20 0.32
PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27052005 0.86 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27052002 0.85 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27052011 0.84 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27052003 0.84 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27051983 0.81 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27052017 0.78 HSD17B10 (0.47) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27051991 0.77 HSD17B10 (0.43) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27051748 0.77 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27051825 0.76 SMN1; SMN2 (0.53) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1
SCHEMBL27051980 0.76 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1SCN4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS SMN1; SMN2 3857/4885RAB9A 63/4885NPC1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.